alexa Adrenoleukodystrophy | India| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Adrenoleukodystrophy

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Adrenoleukodystrophy

    Adrenoleukodystrophy (ALD) refers to several different inherited conditions that affect the nervous system and adrenal glands. Other names for it are adrenomyeloneuropathy, childhood cerebral ALD, and Schilder-Addison Complex. The gene that causes ALD was identified in 1993. It occurs in about 1 in 20,000 people and mainly affects men. Women can carry ALD without having any symptoms. The symptoms, treatments, and prognosis of ALD vary depending on which type is present. ALD is not curable, but the progression can be slowed in some cases.

  • Adrenoleukodystrophy

    Adrenoleukodystrophy (ALD) refers to several different inherited conditions that affect the nervous system and adrenal glands. Other names for it are adrenomyeloneuropathy, childhood cerebral ALD, and Schilder-Addison Complex. The gene that causes ALD was identified in 1993. It occurs in about 1 in 20,000 people and mainly affects men. Women can carry ALD without having any symptoms. The symptoms, treatments, and prognosis of ALD vary depending on which type is present. ALD is not curable, but the progression can be slowed in some cases.

  • Adrenoleukodystrophy

    Globally alcohol consumption accounts for an estimated 3.8% mortality[8]. Although there are varoius causes of death among alcoholics, liver disease stands out as a significant cause of mortality. In 2003, 44% of all deaths from liver disease were attributed to alcohol.Trends in mortality from ALD: Age- and sex adjusted incidence rates of ALD-related deaths decreased from 6.9/100 000 persons in 1980 to 4.4/100 000 persons in 2003. Overall, there is 15% mortality at 30 d and 39% at 1 year[55]. Mortality varies with the disease severity with about 20% in mild forms, and between 30% and 60% in severe AH[56]. In a British study, 30-day mortality rates of less than 20% were observed in patients with mild to moderate disease but exceeded 40% in individuals with severe liver injury

 

High Impact List of Articles

Conference Proceedings